In a bright red market again, Ipsen fell another 6% to 80.8 euros at the start of the week. The title of the laboratory had already dropped 8% Friday following the announcement of a long-term strategic partnership with Genfit. An agreement considered a little expensive paid by the investors. This morning, the biopharmaceutical group is abandoned after a generic of Somatulin, the company’s flagship product, was approved by the American regulator.
The Indian company Cipla said on Sunday that it had received approval from health authorities to market Lanreotide (via an injection), used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, on the American market. This green light from the FDA is not, however, a surprise since Ipsen has long anticipated the gradual launch of generic lanreotide in Europe and the United States.
–
